CompletedNot Applicable

Casein Glycomacropeptide in Active Distal Ulcerative Colitis (Pilot Study)

Denmark24 participantsStarted 2012-01

Plain-language summary

Casein glycomacropeptide (CGMP) has anti-inflammatory properties in experimental rodent colitis and using human in vitro inflammation models. Its use as a food ingredient has proven safe and with no influence on dietary intake. We hypothesize that orally administered CGMP has a beneficial effect comparable to that of mesalazine in active distal ulcerative colitis.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age 18 years or more * Diagnosed ulcerative colitis * Signs of clinical activity with SCCAI of 3 or more * Extension more than 10 cm and no more than 40 cm from anus Exclusion Criteria: * Rectal temperature more than 38 degrees Celcius * Diagnosed celiac disease or lactose intolerance * Unable to speak or understand Danish * Prior biologics or systemic steroids 4 weeks up to inclusion

What they're measuring

Fecal calprotectin reduction

Timeframe: 4 weeks

Trial details

NCT IDNCT01534312

SponsorUniversity of Aarhus

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2014-09

View on ClinicalTrials.gov More Colitis, Ulcerative trials